What does microsatellite instability (MSI) mean for CLL
Microsatellite Instability (MSI) and CLL: What You Should Know
I appreciate this question, but I need to be direct with you: microsatellite instability (MSI) is not a standard biomarker or prognostic factor that's typically evaluated or discussed in chronic lymphocytic leukemia (CLL).
Why MSI Matters in Some Cancers (But Not CLL)
MSI refers to changes in short, repetitive DNA sequences called microsatellites. This biomarker is very important in certain cancers—particularly colorectal cancer and some other solid tumors—where it helps predict treatment response and prognosis.
However, according to the NCCN Guidelines for CLL, the prognostic factors and biomarkers that oncologists actually focus on for CLL are quite different:
Standard CLL Biomarkers Include:
- IGHV mutation status (whether certain genes are mutated)
- Cytogenetic abnormalities (del(17p), del(11q), trisomy 12)
- TP53, NOTCH1, SF3B1, and other genetic mutations
- Complex karyotype (multiple chromosome abnormalities)
- LDH and beta-2-microglobulin levels (blood markers)
These factors help your oncologist understand how aggressive your CLL is and which treatments are most likely to work.
Questions to Ask Your Doctor
If MSI testing has been mentioned in relation to your care:
- "Why was MSI testing ordered for me? Is this related to my CLL or a different concern?"
- "What are the standard biomarkers my team is using to guide my CLL treatment?"
- "Do I have results for IGHV status, cytogenetics, or TP53 mutations? What do those show?"
- "How do my specific genetic findings affect my treatment options?"
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Chronic Lymphocytic Leukemia — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated May 17, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Chronic Lymphocytic Leukemia (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with diagnosis for CLL patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about CLL
- What is the prognosis for metastatic CLL
- What does it mean when CLL spreads to the brain
- Just told my CLL is inoperable — what does that mean
- Can I get disability benefits for CLL
- How do I tell my children I have CLL
- How do I know if my CLL has an actionable mutation
- What is FOLFOX and when is it used for CLL
- What are the signs that CLL has recurred